Recent advances in the management of Takayasu arteritis.
Identifieur interne : 000930 ( Main/Exploration ); précédent : 000929; suivant : 000931Recent advances in the management of Takayasu arteritis.
Auteurs : Durga Prasanna Misra [Inde] ; Anupam Wakhlu [Inde] ; Vikas Agarwal [Inde] ; Debashish Danda [Inde]Source :
- International journal of rheumatic diseases [ 1756-185X ] ; 2019.
Descripteurs français
- KwdFr :
- Antirhumatismaux (effets indésirables), Antirhumatismaux (usage thérapeutique), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Facteur de nécrose tumorale alpha (immunologie), Humains, Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Indice de gravité médicale, Induction de rémission, Maladie de Takayashu (diagnostic), Maladie de Takayashu (immunologie), Maladie de Takayashu (traitement médicamenteux), Produits biologiques (effets indésirables), Produits biologiques (usage thérapeutique), Résultat thérapeutique.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- diagnostic : Maladie de Takayashu.
- effets indésirables : Antirhumatismaux, Immunosuppresseurs, Produits biologiques.
- immunologie : Facteur de nécrose tumorale alpha, Maladie de Takayashu.
- traitement médicamenteux : Maladie de Takayashu.
- usage thérapeutique : Antirhumatismaux, Immunosuppresseurs, Produits biologiques.
- Humains, Indice de gravité médicale, Induction de rémission, Résultat thérapeutique.
English descriptors
- KwdEn :
- Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Biological Products (adverse effects), Biological Products (therapeutic use), Humans, Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Remission Induction, Severity of Illness Index, Takayasu Arteritis (diagnosis), Takayasu Arteritis (drug therapy), Takayasu Arteritis (immunology), Treatment Outcome, Tumor Necrosis Factor-alpha (antagonists & inhibitors), Tumor Necrosis Factor-alpha (immunology).
- MESH :
- chemical , adverse effects : Antirheumatic Agents, Biological Products, Immunosuppressive Agents.
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , immunology : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antirheumatic Agents, Biological Products, Immunosuppressive Agents.
- diagnosis : Takayasu Arteritis.
- drug therapy : Takayasu Arteritis.
- immunology : Takayasu Arteritis.
- Humans, Remission Induction, Severity of Illness Index, Treatment Outcome.
Abstract
Takayasu arteritis (TA) is a challenging large vessel vasculitis to treat. Distinguishing disease activity from vascular damage is difficult, often relying on clinician judgement aided by composite clinical disease activity indices with angiographic evidence of vessel wall thickening or vessel wall hypermetabolism demonstrable on positron emission tomography computerized tomography (PET CT). Glucocorticoids form the mainstay of remission induction. While other conventional disease modifying anti-rheumatic drugs (cDMARDs) or biologic DMARDs (bDMARDs) are commonly used, evidence supporting their usefulness is sparse and generally of low quality. The only two randomized controlled trials (RCT) of a DMARD in TA failed to show efficacy of abatacept in reducing relapses of TA, however, tocilizumab showed a trend towards reduction in time to relapses. Of the cDMARDs, methotrexate, azathioprine, mycophenolate mofetil (MMF), leflunomide and cyclophosphamide have shown clinical efficacy in case series, with some evidence that methotrexate, azathioprine and MMF might retard angiographic progression. Among bDMARDs, anti-tumor necrosis factor alpha agents and tocilizumab may be useful in patients refractory to cDMARDs with retardation of angiographic progression, based on evidence derived from mostly retrospective case series, whereas the role of rituximab and ustekinumab needs further elucidation. Revascularization, either surgical or endovascular, is the treatment of choice to relieve critical, symptomatic stenoses and are best undertaken during inactive disease. Emerging evidence suggests that patients with TA also have increased cardiovascular risk and this requires appropriate management. Large studies involving multiple centers are the need of the hour to appropriately evaluate utility of currently available immunosuppressive therapy in TA.
DOI: 10.1111/1756-185X.13285
PubMed: 30698358
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000511
- to stream PubMed, to step Curation: 000511
- to stream PubMed, to step Checkpoint: 000375
- to stream Ncbi, to step Merge: 001D91
- to stream Ncbi, to step Curation: 001D91
- to stream Ncbi, to step Checkpoint: 001D91
- to stream Main, to step Merge: 000930
- to stream Main, to step Curation: 000930
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent advances in the management of Takayasu arteritis.</title><author><name sortKey="Misra, Durga Prasanna" sort="Misra, Durga Prasanna" uniqKey="Misra D" first="Durga Prasanna" last="Misra">Durga Prasanna Misra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author><author><name sortKey="Wakhlu, Anupam" sort="Wakhlu, Anupam" uniqKey="Wakhlu A" first="Anupam" last="Wakhlu">Anupam Wakhlu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, King George's Medical University, Lucknow, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Rheumatology, King George's Medical University, Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author><author><name sortKey="Agarwal, Vikas" sort="Agarwal, Vikas" uniqKey="Agarwal V" first="Vikas" last="Agarwal">Vikas Agarwal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author><author><name sortKey="Danda, Debashish" sort="Danda, Debashish" uniqKey="Danda D" first="Debashish" last="Danda">Debashish Danda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Immunology & Rheumatology, Christian Medical College Hospital, Vellore, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology & Rheumatology, Christian Medical College Hospital, Vellore</wicri:regionArea><wicri:noRegion>Vellore</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30698358</idno><idno type="pmid">30698358</idno><idno type="doi">10.1111/1756-185X.13285</idno><idno type="wicri:Area/PubMed/Corpus">000511</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000511</idno><idno type="wicri:Area/PubMed/Curation">000511</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000511</idno><idno type="wicri:Area/PubMed/Checkpoint">000375</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000375</idno><idno type="wicri:Area/Ncbi/Merge">001D91</idno><idno type="wicri:Area/Ncbi/Curation">001D91</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D91</idno><idno type="wicri:Area/Main/Merge">000930</idno><idno type="wicri:Area/Main/Curation">000930</idno><idno type="wicri:Area/Main/Exploration">000930</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Recent advances in the management of Takayasu arteritis.</title><author><name sortKey="Misra, Durga Prasanna" sort="Misra, Durga Prasanna" uniqKey="Misra D" first="Durga Prasanna" last="Misra">Durga Prasanna Misra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author><author><name sortKey="Wakhlu, Anupam" sort="Wakhlu, Anupam" uniqKey="Wakhlu A" first="Anupam" last="Wakhlu">Anupam Wakhlu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, King George's Medical University, Lucknow, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Rheumatology, King George's Medical University, Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author><author><name sortKey="Agarwal, Vikas" sort="Agarwal, Vikas" uniqKey="Agarwal V" first="Vikas" last="Agarwal">Vikas Agarwal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author><author><name sortKey="Danda, Debashish" sort="Danda, Debashish" uniqKey="Danda D" first="Debashish" last="Danda">Debashish Danda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Immunology & Rheumatology, Christian Medical College Hospital, Vellore, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology & Rheumatology, Christian Medical College Hospital, Vellore</wicri:regionArea><wicri:noRegion>Vellore</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of rheumatic diseases</title><idno type="eISSN">1756-185X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Biological Products (adverse effects)</term><term>Biological Products (therapeutic use)</term><term>Humans</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Takayasu Arteritis (diagnosis)</term><term>Takayasu Arteritis (drug therapy)</term><term>Takayasu Arteritis (immunology)</term><term>Treatment Outcome</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Tumor Necrosis Factor-alpha (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antirhumatismaux (effets indésirables)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Facteur de nécrose tumorale alpha (immunologie)</term><term>Humains</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Indice de gravité médicale</term><term>Induction de rémission</term><term>Maladie de Takayashu (diagnostic)</term><term>Maladie de Takayashu (immunologie)</term><term>Maladie de Takayashu (traitement médicamenteux)</term><term>Produits biologiques (effets indésirables)</term><term>Produits biologiques (usage thérapeutique)</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antirheumatic Agents</term><term>Biological Products</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Biological Products</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Maladie de Takayashu</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antirhumatismaux</term><term>Immunosuppresseurs</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term><term>Maladie de Takayashu</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Takayashu</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Immunosuppresseurs</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Indice de gravité médicale</term><term>Induction de rémission</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Takayasu arteritis (TA) is a challenging large vessel vasculitis to treat. Distinguishing disease activity from vascular damage is difficult, often relying on clinician judgement aided by composite clinical disease activity indices with angiographic evidence of vessel wall thickening or vessel wall hypermetabolism demonstrable on positron emission tomography computerized tomography (PET CT). Glucocorticoids form the mainstay of remission induction. While other conventional disease modifying anti-rheumatic drugs (cDMARDs) or biologic DMARDs (bDMARDs) are commonly used, evidence supporting their usefulness is sparse and generally of low quality. The only two randomized controlled trials (RCT) of a DMARD in TA failed to show efficacy of abatacept in reducing relapses of TA, however, tocilizumab showed a trend towards reduction in time to relapses. Of the cDMARDs, methotrexate, azathioprine, mycophenolate mofetil (MMF), leflunomide and cyclophosphamide have shown clinical efficacy in case series, with some evidence that methotrexate, azathioprine and MMF might retard angiographic progression. Among bDMARDs, anti-tumor necrosis factor alpha agents and tocilizumab may be useful in patients refractory to cDMARDs with retardation of angiographic progression, based on evidence derived from mostly retrospective case series, whereas the role of rituximab and ustekinumab needs further elucidation. Revascularization, either surgical or endovascular, is the treatment of choice to relieve critical, symptomatic stenoses and are best undertaken during inactive disease. Emerging evidence suggests that patients with TA also have increased cardiovascular risk and this requires appropriate management. Large studies involving multiple centers are the need of the hour to appropriately evaluate utility of currently available immunosuppressive therapy in TA.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Misra, Durga Prasanna" sort="Misra, Durga Prasanna" uniqKey="Misra D" first="Durga Prasanna" last="Misra">Durga Prasanna Misra</name></noRegion><name sortKey="Agarwal, Vikas" sort="Agarwal, Vikas" uniqKey="Agarwal V" first="Vikas" last="Agarwal">Vikas Agarwal</name><name sortKey="Danda, Debashish" sort="Danda, Debashish" uniqKey="Danda D" first="Debashish" last="Danda">Debashish Danda</name><name sortKey="Wakhlu, Anupam" sort="Wakhlu, Anupam" uniqKey="Wakhlu A" first="Anupam" last="Wakhlu">Anupam Wakhlu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000930 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000930 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30698358
|texte= Recent advances in the management of Takayasu arteritis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30698358" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |